Loading...
Loading...
Browse all stories on DeepNewz
VisitU.S. Grants $72 Million to GSK, Sanofi, CSL's Seqirus to Double Bird Flu Vaccines Amid New Cases
Oct 4, 2024, 03:09 PM
Pharmaceutical companies GSK, Sanofi, and CSL Ltd's vaccine division Seqirus have secured $72 million in funding from the U.S. government to accelerate the production of bird flu vaccines. The investment aims to double the number of ready-to-use vaccines available within the first quarter of 2025. U.S. health officials confirmed the funding during a press briefing. This move comes as the U.S. faces increasing cases of H5 avian influenza, with 17 confirmed cases in 2024. Additionally, 254 dairy herds across 14 states have been impacted by the outbreak. The CDC has confirmed two new human cases in California dairy farm workers, who exhibited conjunctivitis but no respiratory symptoms. California health authorities are monitoring other exposed individuals for symptoms.
View original story
Markets
Yes • 50%
No • 50%
California Department of Public Health announcements
Yes • 50%
No • 50%
Centers for Disease Control and Prevention (CDC) reports
Yes • 50%
No • 50%
U.S. government or health department press releases and official statements
Yes • 50%
No • 50%
Reports from the CDC or U.S. health authorities
Yes • 50%
No • 50%
Official announcement from U.S. health authorities or involved pharmaceutical companies
No • 50%
Yes • 50%
Official announcements from U.S. Department of Agriculture or related authorities
Tie • 1%
GSK • 33%
Sanofi • 33%
CSL's Seqirus • 33%
Official production reports from GSK, Sanofi, and CSL's Seqirus
Sanofi • 25%
CSL's Seqirus • 25%
None • 25%
GSK • 25%
U.S. government funding announcements
Texas • 25%
New York • 25%
Other • 25%
California • 25%
CDC and state health department reports
GSK • 33%
Seqirus • 33%
Sanofi • 33%
Official announcements from GSK, Sanofi, or CSL's Seqirus
West • 25%
Midwest • 25%
Northeast • 25%
South • 25%
CDC or U.S. health authority reports categorizing cases by region
Iowa • 25%
Other • 25%
Wisconsin • 25%
California • 25%
Reports from CDC or U.S. health authorities detailing case numbers